Digital Diabetes Management Market to Garner $17.11 Billion: Allied Market Research
March 17, 2020 10:03 ET
|
Allied Market Research
Portland, OR, March 17, 2020 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the Digital Diabetes Management Market accounted for $3.37 billion in 2018 and is projected to...
Novo Nordisk A/S – Share repurchase programme
March 16, 2020 08:43 ET
|
Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 16 March 2020 – On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No...
Generalforsamling
March 16, 2020 08:14 ET
|
Haldor Topsøe A/S
TIL AKTIONÆRERNE I HALDOR TOPSØE A/S, CVR nummer 41853816 Der indkaldes herved til ordinær generalforsamling TIRSDAG DEN 31. MARTS 2020 KL. 16.00 på selskabets adresse, Haldor Topsøes...
Annual General Meeting
March 16, 2020 08:14 ET
|
Haldor Topsøe A/S
TO THE SHAREHOLDERS OF HALDOR TOPSØE A/S, CVR number 41853816 The Board of Directors has the pleasure of convening the Annual General Meeting to be held on TUESDAY MARCH 31, 2020, 16:00...
Global Hormone Replacement Therapy (HRT) Industry
March 12, 2020 11:57 ET
|
ReportLinker
New York, March 12, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hormone Replacement Therapy (HRT) Industry" -...
Global Pediatric Drugs and Vaccines Industry
March 11, 2020 13:14 ET
|
ReportLinker
New York, March 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pediatric Drugs and Vaccines Industry" -...
Innate Pharma reports full year 2019 financial results and business update
March 10, 2020 02:00 ET
|
INNATE PHARMA
INNATE PHARMA REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS UPDATE Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross...
Premier patient traité dans l’essai de Phase I évaluant IPH5201 chez des patients atteints de tumeurs solides avancées
March 10, 2020 02:00 ET
|
INNATE PHARMA
Démarrage du premier essai clinique avec IPH5201, un anticorps monoclonal anti-CD39, première molécule de la collaboration étendue entre Innate et AstraZeneca à avancer au stade clinique Innate...
First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
March 10, 2020 02:00 ET
|
INNATE PHARMA
Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic Innate Pharma SA (Euronext...
Innate Pharma Reports Full Year 2019 Financial Results and Business Update
March 10, 2020 02:00 ET
|
INNATE PHARMA
Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million1)Monalizumab to advance to a Phase...